Oxymetazoline - Aclaris Therapeutics
Alternative Names: AGN-199201; Oxymetazoline hydrochloride; Rhofade; V-101Latest Information Update: 06 Sep 2023
Price :
$50 *
At a glance
- Originator Vicept Therapeutics
- Developer Aclaris Therapeutics; Allergan
- Class Eye disorder therapies; Imidazoles; Small molecules
- Mechanism of Action Alpha 1 adrenergic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Marketed Erythema
- Phase II Presbyopia